Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment

PHASE3RecruitingINTERVENTIONAL
Enrollment

801

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2027

Conditions
Breast Cancer
Interventions
RADIATION

Hypofractionated radiotherapy

4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast

RADIATION

Conventional radiotherapy

5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

collaborator

Shanghai 10th People's Hospital

OTHER

collaborator

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Affiliated Hospital of Jiangnan University

OTHER

collaborator

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

UNKNOWN

collaborator

The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

OTHER

lead

Ruijin Hospital

OTHER

NCT03829553 - Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment | Biotech Hunter | Biotech Hunter